SCHEMBL3065478

SCHEMBL3065478

O=S(=O)(CCc1cccc(Cl)c1F)c1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 1/20 0.58
ALOX12 P18054 4/20 0.57
LMNA P02545 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 1/20 0.49
CYP2C9 P11712 1/20 0.49
EDNRA P25101 1/20 0.49
SLC6A4 P31645 1/20 0.49
ADRA1A P35348 1/20 0.49
PRMT6 Q96LA8 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
SCN9A Q15858 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
PKM P14618 2/20 0.47
SCN1A P35498 3/20 0.46
SCN5A Q14524 3/20 0.46
SCN8A Q9UQD0 3/20 0.46
SCN1B Q07699 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3055803 0.81 LMNA (0.61) SCN3AALOX12LMNASMN1; SMN2ALDH1A1
SCHEMBL3068588 0.80 SCN3A (0.67) SCN3AALOX12LMNASMN1; SMN2ALDH1A1
SCHEMBL3061126 0.78 SCN3A (0.73) SCN3ALMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL3056569 0.75 SCN3A (0.71) SCN3ALMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL3065484 0.75 SCN3A (0.71) SCN3ALMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL18356879 0.74 ALOX12 (0.81) ALOX12LMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL3056051 0.74 SCN3A (0.65) SCN3ALMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL3068460 0.74 SCN3A (0.77) SCN3ALMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL16273104 0.73 SCN3A (0.74) SCN3ALMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL3060426 0.73 SCN3A (1.00) SCN3ALMNASMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140357685-A1 Sodium Channel Inhibitors ICAGEN INC (US) 2014-12-04 US disclosed
US-8853250-B2 Sodium channel inhibitors ICAGEN, INC. (US) 2014-10-07 US disclosed
EP-2175728-B1 SODIUM CHANNEL INHIBITORS ICAGEN INC (US) 2014-09-10 EP disclosed
US-20100267782-A1 SODIUM CHANNEL INHIBITORS ICAGEN, INC (US) 2010-10-21 US disclosed
EP-2175728-A1 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-21 EP disclosed
WO-2009012241-A1 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357685-A1 Sodium Channel Inhibitors TRPV1, SCN1A, SCN2A SCN3A 8/4885ALOX12 1353/4885LMNA 3041/4885
US-20100267782-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A SCN3A 8/4885ALOX12 1353/4885LMNA 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.